Delving into the Latest Updates on MAG-200 with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms

MAG 200, MAG200

Target-

Mechanism

Cell replacements

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Osteoarthritis

Originator Organization

Magellan Biosciences, Inc.

Active Organization-

Inactive Organization

Magellan Biosciences, Inc.

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Author: Wickham, James ; Cicuttini, Flavia ; Kenihan, Michael ; Wickramasinghe, Iresha ; Grogan, Melissa ; Picken, Ellee ; Chamberlain, Matthew ; Solterbeck, Ann ; Lutz, Carla ; Freitag, Julien ; Castelluccio, Renee ; Kelly, Lesley-Anne ; Wang, Yuanyuan ; George, Teena ; Tenen, Abi ; Shah, Kiran ; Kenihan, Lucinda ; Shah, Nirali

Objectives:

To assess the safety and efficacy of an allogeneic adipose-derived mesenchymal stem cell preparation (MAG200) in the treatment of knee osteoarthritis over 12 months.

Design:

A single-centre, double-blind, ascending dose, randomised controlled trial. 40 participants with moderate knee osteoarthritis were randomised to receive a single intra-articular injection of MAG200 (dose cohorts:10, 20, 50, 100 × 10⁶ cells) or placebo. Primary objectives were safety and efficacy according to a compound responder analysis of minimal clinically important difference in pain (numerical pain rating scale [NPRS]) and function (Knee Injury and Osteoarthritis Outcome Score - Function in Daily Living subscale [KOOS_ADL]) at month 12. Secondary efficacy outcomes included changes from baseline in patient reported outcome measures and evaluation of disease-modification using quantitative MRI.

Results:

Treatment was well tolerated with no treatment-related serious adverse events. MAG200 cohorts reported a greater proportion of responders than placebo and demonstrated clinical and statistically significant improvement in pain and clinically relevant improvement in all KOOS subscales. MAG200 demonstrated a reproducible treatment effect over placebo, which was clinically relevant for pain in the 10 × 10⁶ dose cohort (mean difference NPRS:-2.25[95%CI:-4.47,-0.03, p = 0.0468]) and for function in the 20 × 10⁶ and 100 × 10⁶ dose cohorts (mean difference KOOS_ADL:10.12[95%CI:-1.51,21.76, p = 0.0863] and 10.81[95%CI:-1.42,23.04, p = 0.0810] respectively). A trend in disease-modification was observed with improvement in total knee cartilage volume in MAG200 10, 20, and 100 × 10⁶ dose cohorts, with progression of osteoarthritis in placebo, though this was not statistically significant. No clear dose response was observed.

Conclusion:

This early-phase study provides supportive safety and efficacy evidence to progress MAG200 to later-stage trial development.

Trial registration:

ACTRN12617001095358/ACTRN12621000622808.

01 Jan 2013·World journal of gastroenterologyQ3 · MEDICINE

Promising effect of Magliasa, a traditional Iranian formula, on experimental colitis on the basis of biochemical and cellular findings

Q3 · MEDICINE

Article

Author: Amin ; Baeeri ; Mohammad ; Rahimi ; Khanavi ; Roja ; Maryam ; Reza ; Gholamreza ; Shams-Ardekani ; Abdollahi ; Amir ; Baghaei ; Mahnaz

AIM:

To investigate the efficacy of Magliasa, a traditional Iranian formula, on experimental colitis.

METHODS:

After botanical authentication of herbal ingredients, formulation of Magliasa, quantitative determination of total glucosinolates and total phenolic content, and analysis of the thin layer chromatography profile were performed. Colitis was then induced in male rats by instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS) in all groups, aside from the Sham group. The experimental groups consisted of: the Sham group that received only normal saline; the Mag-50, Mag-100 and Mag-200 groups, which received 50, 100 and 200 mg/kg per day of Magliasa, respectively; the control group, which received vehicle water orally; the infliximab group, which received infliximab (5 mg/kg per day, subcutaneously); and the Dexa group, which received dexamethasone (1 mg/kg per day, orally). After completing the treatment period (2 wk), the rats were sacrificed, the colon was removed, its macroscopic and microscopic changes were recorded, and tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), total antioxidant capacity, myeloperoxidase (MPO), and lipid peroxidation (LPO) were assessed in colon homogenate.

RESULTS:

The mean value of total glucosinolates in one gram of Magliasa was 19 ± 1 μmol. The mean value of the total phenolic content was 293.8 ± 17.6 mg gallic acid equivalents per 100 gram of Magliasa. Macroscopic scores were significantly decreased in Mag-100 (1.80 ± 0.58, P = 0.019) and Mag-200 (1.20 ± 0.20, P = 0.001) compared to the control group (3.40 ± 0.24), although some inflammation and hyperemia were evident. Treatment of rats by dexamethasone (0.33 ± 0.21, P < 0.001) and infliximab (0.83 ± 0.31, P < 0.001) remarkably attenuated scores where mild hyperemia was observed macroscopically. In comparison to the control group (4.00 ± 0.32), only Mag-200 (1.60 ± 0.40) showed a significant decrease in colonic histopathological scores (P = 0.005). Minimal mucosal inflammation was observed in the Dexa group (0.67 ± 0.21, P < 0.001). The levels of TNF-α, IL-1β and MPO were significantly lower in all groups compared to the controls (P < 0.05). A significant decrease in LPO was seen in the Mag-200 (3.27 ± 0.77, P = 0.01) and Dexa (3.44 ± 0.22, P = 0.011) groups in comparison to the control group (6.43 ± 0.61). Only dexamethasone caused a significant increase in antioxidant power in comparison to the control group (346.73 ± 9.9 vs 228.33 ± 2.75, P < 0.001). Infliximab and different doses of Magliasa did not show any remarkable increase in antioxidant capacity (P > 0.05). The effect of Magliasa in all of mentioned parameters, except antioxidant capacity, was dose dependent.

CONCLUSION:

The effects of Magliasa in TNBS-induced colitis are encouraging and warrant clinical trials for further confirmation.

100 Deals associated with MAG-200

Login to view more data